-
Johnson & Johnson 2022Q3: blockbuster products face patent cliff, ibrutinib is "besieged
Time of Update: 2022-10-31
Sales of ustekinumab, a blockbuster product in the field of self-exemption, exceeded $2 billion, but the patent cliff is coming In the third quarter, Johnson & Johnson's self-immunity revenue was $4.
-
Over 10%! Sales of 98 brands of drugs over 100 million soared
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; According to the latest data from Intranet, the sales scale of terminal chemical drugs in public hospitals in key provinces and cities in the first half of 2022 exceeded 100 billion yuan, a slight decline from the same period last year.
-
The nearly 10 billion US dollar drug market is attracting many pharmaceutical companies
Time of Update: 2022-10-19
In August 2017, the product entered the Chinese market and has been approved for the treatment of patients with mantle cell lymphoma, chronic lymphoblastic leukemia, small lymphocytic lymphoma and Waldenstrom macroglobulinemia.
-
Huahai Pharmaceutical's Metoprolol Succinate Sustained-Release Tablets and Silodosin Capsules were approved by the US FDA
Time of Update: 2022-03-09
On January 6, Huahai Pharmaceutical issued an announcement saying that the abbreviated new drug application for metoprolol succinate sustained-release tablets and silodosin capsules submitted by the company to the US FDA has been approved .
-
Blood: ICSD activation disorder induces p53 dependent MCL-1 degradation and MYC-driven lymphoma death
Time of Update: 2021-02-01
In order to determine whether Ribi can be used as a therapeutic target for lymphoma, Domostegui and others have established E-Myc lymphoma cells that express the induced shRNA of ribosome protein (RP) L7a or RPL11, an important component of IRBC.
-
Qilu Pharmaceuticals Class 4 generic drug "Pybersili Capsules" has been approved for market
Time of Update: 2020-12-30
the approval of Qilu's Pybersili generic drug, which means that the country ushered in the first domestic CDK4/6 inhibitors, breast cancer patients will usher in new treatment options.
-
Head and neck cancer has ushered in a new breakthrough in treatment that has not been expected in a decade
Time of Update: 2020-12-28
On December 11th, the official website of China's State Drug Administration (NMPA) showed that the Merca East PD-1 inhibitor Paboliju monoanti (commodity name: Corida) had been approved for use in assessing tumor expression PD through fully validated testing -L1 (comprehensive positive score (CPS)≥20) metastatic or non-removable relapsed head and neck squamous cell carcinoma (HNSCC) patients first-line treatment, became the first immune first-line treatment of head and neck squamous cancer.
-
In vivo (liver) human genome editing tests were conducted in the first clinical trial
Time of Update: 2020-09-03
"Macrae said, one advantage of Sangamo's strategy in current clinical trials is that it is "a lifelong solution." once these functional copies of the ZFN-promoting F9 gene are integrated into the participants' liver cell genomes, the gene should be expressed steadily.
-
Engage Therapeutics innovative inhalation therapy reaches the clinical end of Phase 2b
Time of Update: 2020-08-01
Staccato alprazolam (Photo Source: Engage Therapeutics) StATES Trial is a randomized, double-blind phase 2b clinical study involving 116 patients to assess the safety, effectiveness and availability of Staccato alprazolam in the treatment of adults with terretomy or systemic seizures.
-
AXS-05 approved by FDA for breakthrough therapy for Alzheimer's disorder
Time of Update: 2020-07-14
Biopharmaceutical company Axsome recently announced that the U.S Food and Drug Administration Administration ( FDA ) has awarded AXS-05 breakthrough therapy for the treatment of Alzheimer's disea
-
cSCC immunotherapy! Merck's Keytruda new indication has been approved by the US FDA
Time of Update: 2020-07-11
Original source: FDAapproves Merck's keytruda ® (pembrolizumab) for the treatment of the patient s with Recurrent or Metastatic Cution Squamous Cell Carcinoma (cSCC) is Thatable Cur Surgery or Radiati
-
R & D Daily: the first clinical application of innovative compound liposome preparation in China has been accepted
Time of Update: 2020-06-19
[June 12, 2020, R & D news] the new crown vaccine of Moderna is determined to be a three-phase clinical trial plan, which is expected to start in July; Roche CPAM and TLR7 agonist combination therapy
-
Strive for first listing BioMarin suspends haemophilia gene therapy Valrox low-dose study
Time of Update: 2020-06-08
In order to become the world's first hemophilia gene therapy, BioMarin has announced the abandonment of the development of low-dose Valoccogene roxaparvec The company now plans to submit accelerated a
-
AstraZeneca Fasenra automatic injection pen approved by FDA can be self-injected at home
Time of Update: 2020-06-01
Fasenra's self-administering options and Pasenra pen have also been approved in the European Union Fasenra is currently approved as an additional (add-on) maintenance therapy in the United States, the
-
FDA approves Takeda's tyrosine kinase inhibitor ALUNBRIG (brigatinib), first-line treatment of ALK-positive metastatic non-small cell lung cancer patients
Time of Update: 2020-05-29
Takeda announced that the U.S Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor (TKI) ALUNBRIG (brigatinib) for metastatic lymphoma kinase-positive (ALK-positive) patien
